Article
The genetics and kinetics of BCL2 driven lymphoid malignancies
2015-01-01
Abstract excerpt
Introduction: Non-Hodgkin Lymphoma (NHL) is rising in incidence. Treatment of this genetically heterogeneous disease has toxic side effects and significant numbers of relapsers / non-responders. BCL2, an anti-apoptotic protein, is commonly overexpressed in NHL as a result of the t(14;18) translocation. A number of BCL2 inhibitors have shown success in clinical trials but variable efficacy has meant that none have...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 6bbaf751-7647-5615-be12-8211a437ff28
- DOI
- 10.25560/45406
